Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489.

Cells - 26 Dec 2023

Soung Young Hwa, Ju Jingfang, Chung Jun

Abstract excerpt

Chemoresistance and inefficient therapeutic efficacies in triple-negative breast cancers (TNBCs) are among the major clinical problems in breast cancers. A potential new method to sensitize these tumors to current treatment options is, therefore, urgent and necessary. Our previous studies demonstrated that miR-489 serves as one of the top tumor-suppressing miRs and features downregulated expression in metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to MicroRNAs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38201253
DOI: 10.3390/cells13010049
PMCID: PMC10778461

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489.PMID 38201253Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and CisplatinSemantic proximity Read ↗

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.Semantic proximity Read ↗

DNA damage response inhibitors: An avenue for TNBC treatment.Semantic proximity Read ↗

Efficacy and Mechanism of the Combination of PARP and CDK4/6 Inhibitors in the Treatment of Triple-negative Breast CancerSemantic proximity Read ↗

AZD6738 overcomes acquired olaparib resistance in BRCA1 mutation triple-negative breast cancer through down-regulation of BRCA2 and RAD51.Semantic proximity Read ↗

Poly (adenosine diphosphate‐ribose) polymerase inhibitors in the treatment of triple‐negative breast cancer with homologous repair deficiencySemantic proximity Read ↗

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast CancerSemantic proximity Read ↗

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expressionSemantic proximity Read ↗

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cellsSemantic proximity Read ↗

Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair.Semantic proximity Read ↗

Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.